ClinicalTrials.gg
RecruitingNCT07433504Updated Feb 25, 2026

A Prospective, Multicenter, Randomized Controlled Clinical Trial of Transcatheter Tricuspid Valve Clipping Systems.

An interventional study of Experimental: Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT and Guideline Directed Medical Therapy in Severe or Greater Tricuspid Regurgitation, sponsored by Shanghai Huihe Medical Technology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Shanghai Huihe Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Tricuspid Valve Insufficiency with a site in China — 19 open to participants now, 21 under way, none of them phase 3. Tricuspid Valve Insufficiency · China.

Planned enrollment
8th of 16
132 · median 129
Started
2026
with 4 others
No phase
15 of 28
9 open now
Primary completion
2027-12
later than 11 of 20 live
Registered
22nd of 28
by date
Lead sponsor
2 of 28
Shanghai Huihe Medical Technology Co., Ltd

Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, this one is the 8th largest by planned enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 with no phase, reaches primary completion later than 11 of the 20 other live ones, and was the 22nd registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

19 of the 28 studies in Tricuspid Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Tricuspid Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

The transcatheter tricuspid valve clipping system is specially designed for the treatment of tricuspid regurgitation. Under the guidance of ultrasound and DSA imaging, the investigational device is advanced into the right ventricle via a femoral or jugular venous puncture approach. The clipping component grasps the edges of the dysfunctional valve leaflets (usually unable to close properly), thereby reducing the area of the tricuspid orifice that fails to coapt normally, achieving minimally invasive treatment of tricuspid regurgitation.

03

Conditions studied

  • Severe or Greater Tricuspid Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, male or female;
  2. Patients with severe or greater tricuspid regurgitation (TR ≥ 4+) judged by the local study team to have received adequate treatment according to applicable standards and remained stable for at least 30 days (TR grading to be determined by the core laboratory);

    Adequate treatment is defined as:

    Oral diuretic therapy for tricuspid regurgitation at a stable dose for at least 30 days; Guideline-directed medical therapy for heart failure (if applicable) according to heart failure subtype with different , at a stable dose for at least 30 days; For subjects with mitral regurgitation (MR ≥ 3+), atrial fibrillation, or coronary artery disease: medical therapy for ≥ 30 days, or ≥ 30 days post device-based therapy with stable clinical status.

    Stable dose is defined as: dose increase ≤ 100% or dose reduction ≤ 50%.

  3. The multidisciplinary heart team (comprising cardiologists, cardiovascular surgeons, imaging specialists, anesthesiologists, etc., with at least 2 physicians) judges that the subject is at moderate or high surgical risk (Tri-Score ≥ 4.0) and is expected to benefit from tricuspid edge-to-edge repair;
  4. Left ventricular ejection fraction (LVEF) ≥ 20%;
  5. Presence of symptoms attributable to tricuspid regurgitation (e.g., chest distress, dyspnea, shortness of breath, lower extremity edema, ascites), or asymptomatic subjects with right ventricular dilation or impaired right ventricular function (as determined by the core laboratory);
  6. Impaired right ventricular function is defined as: tricuspid annular plane systolic excursion (TAPSE) \< 17 mm or fractional area change (FAC) \< 35%.

    functional class II to IV, inclusive;

  7. Subject voluntarily agrees to participate in the clinical trial and provides written , or consent is provided by the subject's legal representative.

Exclusion criteria

Exclusion Criteria:

  1. Patients with pulmonary artery systolic pressure ≥ 60 mmHg: if right heart catheterization was performed, results shall be based on right heart catheterization; if not performed, results shall be based on echocardiography (assessed by the core laboratory).
  2. Tricuspid valve anatomy that, in the judgment of the core laboratory, may preclude implantation, proper positioning of the tricuspid clip device, fail to sufficiently reduce TR severity, or achieve adequate leaflet apposition, including but not limited to:

    Severe calcification in the leaflet grasping zone; Severe leaflet perforation, cleft, or other lesions that impede device implantation; Ebstein's anomaly; TR expected to be unamenable to reduction to grade 2+ or lower post-procedure with edge-to-edge repair.

  3. Presence of a prosthetic valve or annuloplasty ring at the tricuspid valve position, or prior tricuspid valve surgery that, in the judgment of the core laboratory, would interfere with study device implantation or therapeutic effect.
  4. Tricuspid stenosis, defined as tricuspid valve area ≤ 1.0 cm² and/or mean tricuspid gradient > 5 mmHg (assessed by the core laboratory).
  5. Tricuspid valve anatomy that cannot be evaluated by transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE).
  6. Evidence of mass, thrombus, or vegetation in the cardiac chambers, access-related veins (jugular or femoral vein, depending on the selected access route for the individual subject), superior vena cava, or inferior vena cava (depending on the selected access route for the individual subject).
  7. Patients in whom bilateral femoral veins are unsuitable for 23 Fr sheath access due to disease or anatomy, and bilateral jugular veins are unsuitable for 21 Fr sheath access (i.e., both transfemoral and transjugular access are ).
  8. Severe uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg).
  9. Prior implantation of a pacemaker (excluding leadless pacemakers) or implantable cardioverter-defibrillator (ICD), or planned implantation of a pacemaker (excluding leadless pacemakers) or ICD that, in the judgment of the core laboratory, would interfere with study device implantation or therapeutic effect, or where study device implantation would interfere with the pacemaker or ICD.
  10. Hemodynamic instability, defined as systolic blood pressure \< 90 mmHg, cardiogenic shock, requirement for inotropic support, intra-aortic balloon pump, or other hemodynamic support devices.
  11. End-stage heart failure requiring specialized interventions (e.g., mechanical circulatory support, heart transplantation, etc.).
  12. Patients with more than moderate aortic stenosis, mitral stenosis, aortic regurgitation, or mitral regurgitation; or patients scheduled for cardiac surgery within the next 12 months.
  13. Percutaneous coronary intervention within the previous 1 month.
  14. Myocardial infarction within the previous 1 month or known unstable angina.
  15. Cerebrovascular accident within the previous 3 months.
  16. Patients with active infective endocarditis or active rheumatic heart disease.
  17. Patients with coagulopathy, hypercoagulable state, or anemia ( \< 90 g/L).
  18. Patients with acute infection or other severe infection.
  19. Patients with active peptic ulcer or active gastrointestinal bleeding.
  20. (TIA) within 30 days, or prior stroke with permanent disability (mRS > 4).
  21. Severe end-stage disease (e.g., malignant tumor, severe pulmonary disease, hepatic disease, renal failure) with \< 1 year.
  22. Patients with known or contraindications to the study device materials or study medications (e.g., antiplatelet agents, anticoagulants).
  23. Alcohol, drug, or substance addiction.
  24. Patients with cognitive impairment.
  25. History of primary or persistent epilepsy poorly controlled by medication, or psychiatric disorders.
  26. Participation in any other clinical trial (except registry studies) within 30 days prior to signing the form.
  27. Chronic dialysis patients.
  28. Females who are pregnant, breastfeeding, or planning to become pregnant during the clinical trial.
  29. Any other conditions deemed inappropriate by the investigator for participation in this clinical trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT

    Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT

    Device: Experimental: Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT

  • Active comparator
    Guideline Directed Medical Therapy

    GDMT

    Drug: Guideline Directed Medical Therapy

Interventions

  • DeviceExperimental: Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT

    This is a prospective, multi-center, randomized controlled clinical trial. Eligible patients with severe or greater tricuspid regurgitation will be enrolled in accordance with the inclusion and exclusion criteria specified in the study protocol. A total of 132 patients who meet all inclusion criteria and none of the exclusion criteria during pre-treatment screening will be randomized in a 2:1 ratio to either the experimental group or the control group.

  • DrugGuideline Directed Medical Therapy

    Guideline Directed Medical Therapy

06

What researchers measure

Primary outcomes

  1. Rate of subjects free of all-cause death or tricuspid valve reoperation, free of heart failure readmission, and with ≥15-point improvement in the Kansas City Cardiomyopathy Questionnaire score at 1 year after treatment.

    Time frame: at 1 year after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2027, 23 months later.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 23 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Feb 25, 2026
StartEst.
Jan 28, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2031
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07433504
Lead sponsor
Shanghai Huihe Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Jan 28, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Feb 25, 2026

Study contacts

Tina Chen
Contact
tina.chen@hh-healthcare.com
+86-15986752781
Junbo Ge
Contact
021-60046990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion